Todd Yezefski

546 total citations
34 papers, 329 citations indexed

About

Todd Yezefski is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Todd Yezefski has authored 34 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 12 papers in Surgery and 10 papers in Oncology. Recurrent topics in Todd Yezefski's work include Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Todd Yezefski is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Todd Yezefski collaborates with scholars based in United States, Spain and Canada. Todd Yezefski's co-authors include Veena Shankaran, Dan Sherman, Kate Watabayashi, José R. Conejo-García, Asli Silahtaroglu, Wendy A. Wells, Murray Korc, Lorenzo F. Sempere, Haoxu Ouyang and Sakari Kauppinen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Todd Yezefski

32 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd Yezefski United States	8	101	98	98	80	69	34	329
Jennifer M. Suga United States	11	64 0.6×	73 0.7×	61 0.6×	206 2.6×	132 1.9×	40	346
John Waller United Kingdom	10	41 0.4×	57 0.6×	76 0.8×	107 1.3×	102 1.5×	38	415
D. Greenberg United Kingdom	8	48 0.5×	46 0.5×	35 0.4×	208 2.6×	70 1.0×	13	361
Ryan Huey United States	11	49 0.5×	45 0.5×	59 0.6×	215 2.7×	58 0.8×	38	342
Francis V. James India	9	42 0.4×	94 1.0×	48 0.5×	95 1.2×	40 0.6×	33	304
Colleen Lewis United States	9	36 0.4×	139 1.4×	30 0.3×	170 2.1×	64 0.9×	27	406
Ghulam Haider Pakistan	11	34 0.3×	54 0.6×	20 0.2×	91 1.1×	52 0.8×	62	291
Derrick S. Haslem United States	9	175 1.7×	54 0.6×	37 0.4×	208 2.6×	154 2.2×	30	459
Yeun Mi Yim United States	11	36 0.4×	68 0.7×	94 1.0×	270 3.4×	139 2.0×	27	427
Andrew Schmidt United States	10	56 0.6×	66 0.7×	24 0.2×	126 1.6×	109 1.6×	30	267

Countries citing papers authored by Todd Yezefski

Since Specialization

Citations

This map shows the geographic impact of Todd Yezefski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Yezefski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Yezefski more than expected).

Fields of papers citing papers by Todd Yezefski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Yezefski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Yezefski. The network helps show where Todd Yezefski may publish in the future.

Co-authorship network of co-authors of Todd Yezefski

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Yezefski. A scholar is included among the top collaborators of Todd Yezefski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Yezefski. Todd Yezefski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khaki, Ali Raza, Mary W. Redman, Kelsey K. Baker, et al.. (2025). Neoadjuvant pembrolizumab (pembro) and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in non-urothelial (non-UC) histologic subtype muscle invasive bladder cancer (MIBC): A phase 2 trial.. Journal of Clinical Oncology. 43(5_suppl). 769–769.

Cheng, Heather H., Roman Gulati, Michael T. Schweizer, et al.. (2025). Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency. European Urology Oncology. 9(1). 37–44. 1 indexed citations

Gulati, Roman, Heather H. Cheng, Andrew C. Hsieh, et al.. (2025). VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer.. Journal of Clinical Oncology. 43(16_suppl).

Bakaloudi, Dimitra Rafailia, Fady Ghali, Yaw A. Nyame, et al.. (2024). Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer. 22(3). 102100–102100. 3 indexed citations

Mo, George, Laura Graham, Roman Gulati, et al.. (2024). Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study. JCO Precision Oncology. 8(8). e2300634–e2300634. 7 indexed citations

Gulati, Roman, Heather H. Cheng, Jessica E. Hawley, et al.. (2024). Hematologic toxicity in ¹⁷⁷lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV).. Journal of Clinical Oncology. 42(16_suppl). 5075–5075. 3 indexed citations

Gulati, Roman, Jessica E. Hawley, Todd Yezefski, et al.. (2024). SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving¹⁷⁷Lu-PSMA-617. Journal of Nuclear Medicine. 65(12). jnumed.124.267665–jnumed.124.267665. 4 indexed citations

Gulati, Roman, Peter S. Nelson, Heather H. Cheng, et al.. (2024). Association between SPECT/CT total tumor volume (TTV) and new lesions (NLs) in early cycles of ¹⁷⁷Lu-PSMA-617 (LuPSMA) and progression-free and overall survival (PFS and OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 40–40. 1 indexed citations

Gulati, Roman, Fatemeh Behnia, Peter S. Nelson, et al.. (2024). PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received¹⁷⁷Lu-PSMA-617: Importance of¹⁸F-FDG–Avid Discordant Findings. Journal of Nuclear Medicine. 66(1). 47–53. 4 indexed citations

10.

Holt, Sarah K., Dattatraya Patil, Ryan B. O’Malley, et al.. (2024). A Multicenter Evaluation of Treatment-associated Changes in Body Composition in Men With Germ Cell Tumors of the Testis: Implications for Adverse Events and Complications. Urology. 192. 74–82. 1 indexed citations

11.

Zeng, Jing, Jiajun Chen, Emily S. Weg, et al.. (2023). Proton Radiation Therapy for Stage IIA/IIB Testicular Seminoma. International Journal of Radiation Oncology*Biology*Physics. 117(2). e411–e412. 1 indexed citations

12.

Cheng, Heather H., Alexandra Sokolova, Roman Gulati, et al.. (2023). Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer. JCO Precision Oncology. 7(7). e2200104–e2200104. 14 indexed citations

13.

O’Malley, Ryan B., Sarah K. Holt, George R. Schade, et al.. (2022). Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events. Urologic Oncology Seminars and Original Investigations. 40(10). 456.e19–456.e30. 6 indexed citations

14.

Dash, Atreya, William J. Ellis, Jonathan J. Chen, et al.. (2022). Clinical impact of PSMA PET in patients with biochemically recurrent prostate cancer after locoregional definitive therapy.. Journal of Clinical Oncology. 40(16_suppl). e17009–e17009. 2 indexed citations

15.

Schweizer, Michael T., Roman Gulati, Todd Yezefski, et al.. (2021). 592P Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 32. S639–S640. 3 indexed citations

16.

Diamantopoulos, Leonidas Nikolaos, Ali Raza Khaki, Petros Grivas, et al.. (2020). Plasmacytoid Urothelial Carcinoma: Response to Chemotherapy and Oncologic Outcomes. Bladder Cancer. 6(1). 71–81. 26 indexed citations

17.

Yezefski, Todd, et al.. (2018). Impact of trained oncology financial navigators on patient out-of-pocket spending.. PubMed. 24(5 Suppl). S74–S79. 85 indexed citations

18.

Yezefski, Todd, et al.. (2017). Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. Seminars in Hematology. 55(4). 185–188. 30 indexed citations

19.

Yezefski, Todd, Hu Xie, Pamela S. Becker, et al.. (2013). Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. Blood. 122(21). 5002–5002. 1 indexed citations

20.

Sempere, Lorenzo F., Meir Preis, Todd Yezefski, et al.. (2010). Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors. Clinical Cancer Research. 16(16). 4246–4255. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact